Skip to Content

Legal Notice

Acceptance of Agreement.

Your access to and use of www.lillyADresearch.com website (the “Site”), which is maintained by Clinical Trial Media, Inc. (www.clinicaltrialmedia.com), is subject to the following terms and conditions and all applicable laws. By accessing and browsing the Site, you accept and agree to, without limitation or qualification, the terms and conditions and acknowledge that any other agreements between you and Clinical Trial Media are superseded and of no force or effect with respect to your access and use of the Site. 

Scope of Use.

Clinical Trial Media maintains the Site for your personal information, education, and communication. Please feel free to browse the Site. You may download material displayed on the Site for non-commercial, personal use only, provided you maintain all copyright and other proprietary notices on the materials. You may not, however, distribute, modify, transmit, reuse, repost or use the content of the Site for commercial purposes, including the text and images, without Clinical Trial Media’s written permission. You understand that Clinical Trial Media makes no representation that the information in the Site is appropriate or available for use in locations outside of the United States, and access to the Site from territories where the content of the Site may be illegal or inappropriate is prohibited. Those who choose to access the Site from other locations do so on their own initiative and are responsible for compliance with applicable local laws.

No Medical Advice.

The Site does not provide medical advice. With limited exception, any products discussed on the Site are available only by prescription from a licensed health care professional. The Site is not engaged in rendering medical or similar professional services or advice, and the information provided on the Site is not intended to replace medical advice offered by a healthcare provider. If you desire or need such services or advice, you should promptly consult a physician or professional health care provider. 

Copyright Protection.

You should assume that everything you see or read on the Site is copyrighted, unless otherwise noted, and may not be used except as provided in these terms and conditions or in the text on the Site without the written permission of the Site. The Site neither warrants nor represents that your use of materials displayed on the Site will not infringe rights of third parties not owned by or affiliated with the Site.  

Trademarks.

The trademarks, trade names, logos and service marks (collectively the “Trademarks”) displayed on the Site are registered and unregistered Trademarks of Clinical Trial Media and others. Nothing contained on the Site should be construed as granting, by implication, estoppel or otherwise, any license or right to use any Trademark displayed on the Site without the written permission of Clinical Trial Media or any third party that may own the Trademarks displayed on the Site. Your use of the Trademarks displayed on the Site, or any other content on the Site, except as provided in these terms and conditions, is strictly prohibited. You are also advised that Clinical Trial Media will aggressively enforce its intellectual property rights to the fullest extent of the law, including the seeking of criminal prosecution.

Exclusion of Warranty.

While Clinical Trial Media uses reasonable efforts to include accurate and up-to-date information in the Site, Clinical Trial media makes no warranties or representations as to its accuracy. Clinical Trial media assumes no liability or responsibility for any errors or omissions in the content of the Site. Without limiting the foregoing, everything on the Site is provided to you “AS IS” WITHOUT WARRANTY OF ANY KIND, EITHER EXPRESSED OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR NON-INFRINGEMENT. Please note that some jurisdictions may not allow the exclusion of implied warranties, so some of the above exclusions may not apply to you.  Check your local laws for any restrictions or limitations regarding the exclusion of implied warranties.

Limitation of Liability.

Your use of and browsing in the Site are at your risk. Neither the Site nor any other party involved in creating, producing or delivering the Site is liable for any direct, incidental, consequential, indirect or punitive damages arising out of your access to, or use of, the Site. The Site and/or Clinical Trial Media assume no responsibility, and shall not be liable for, any damages to, or viruses that may infect, your computer equipment or other property on account of your access to, use of, or browsing in the Site or your downloading of any materials, data, text or images from the Site.

Prohibited Transmissions.

Certain areas of the Site may enable you to access online forums and to submit e-mails, or otherwise provide feedback to the Site. Clinical Trial Media does not endorse, and specifically disclaims, any responsibility or liability for any content in these forays. You may not post or transmit any unlawful, threatening, libelous, defamatory, obscene, indecent, inflammatory, pornographic or profane material or any material that could constitute or encourage conduct that would be considered a criminal offense, give rise to civil liability or otherwise violate any law. In addition, you are prohibited from posting or transmitting any information which (a) infringes the rights of others or violates their privacy or publicity rights, (b) is protected by copyright, trademark or other proprietary right, unless with the express written permission of the owner of such right, (c) contains a virus, bug or other harmful item, or (d) is used to unlawfully collude against another person in restraint of trade or competition. You shall be solely liable for any damages resulting from any infringement of copyright, trademark, or other proprietary right, or any other harm resulting from your use of the Site.

Use Submissions.

Any personal data (including PIHI) in electronic communications to the Site is governed by the Site’s Privacy Policy. On the other hand, any communication or material you transmit to the Site by electronic mail or otherwise, including any non-personal data, questions, comments, suggestions or the like is, and will be treated as, non-confidential and non-proprietary. You understand that any such communication or material you transmit or post may be used by Clinical Trial Media or its affiliates for any purpose, including but not limited to, reproduction, disclosure, transmission, publication, broadcast, and posting. Furthermore, Clinical Trial Media is free to use any ideas, concepts, know-how, processes, or techniques contained in any communication you send to the Site for any purpose whatsoever including, but not limited to, developing, manufacturing, marketing, and selling products and service using such ideas, concepts, know-how, processes, or techniques.

Links to Other Sites.

Clinical Trial Media has not reviewed all of the sites linked to the Site and is not responsible for the content of any off-site pages or any other sites linked to the Site. Your linking to any other off-site pages or other sites is at your own risk. Once you link to another site, please be sure to review the legal notice and privacy policy of the new site. It may be different from those governing the Site.

Modification of Agreement.

Clinical Trial Media may, at any time, revise the terms and conditions of this agreement governing use of the Site. If any terms and conditions contained in this Legal Notice are changed, the amended notice will be posted on the Site. You are bound by any such revisions and should, therefore, periodically review these terms and conditions.

Let’s discover what’s possible together.

ESTÁ SALIENDO DE ESTE SITIO WEB

Está saliendo de lillyadresearch.com/es-us/ y se le redirigirá a un sitio web que no es operado por Clinical Trial Media, Inc. Tenga en cuenta que Clinical Trial Media, Inc. no es responsable por el contenido ni la disponibilidad de este sitio web, y que sus políticas de privacidad y seguridad podrían ser diferentes de las de nuestro sitio web.

ESTÁ SALIENDO DE ESTE SITIO WEB

Está saliendo de lillyadresearch.com/es-us/ y se le redirigirá a un sitio web que no es operado por Clinical Trial Media, Inc. Tenga en cuenta que Clinical Trial Media, Inc. no es responsable por el contenido ni la disponibilidad de este sitio web, y que sus políticas de privacidad y seguridad podrían ser diferentes de las de nuestro sitio web.

Estos son los objetivos que guían el trabajo de Lilly:

Crear una estrategia sólida para los estudios de investigación clínica y llegar a poblaciones diversas:

Nuestros equipos buscan que los participantes de cada estudio reflejen la composición de la población de pacientes que podrían usar el medicamento del estudio si se lo aprueba. En los distintos estudios de todo el mundo, identificamos y abordamos los obstáculos que impiden la participación de ciertas poblaciones que normalmente tienen una representación menor.

Seleccionar intencionalmente un rango diverso de centros e investigadores:

Buscamos incorporar más investigadores y asesores externos que representen a las mujeres y las poblaciones de minorías raciales y étnicas en los estudios. Nuestro objetivo máximo es que en nuestros grupos de investigadores y asesores se refleje la composición de la población de pacientes en términos de género y raza u origen étnico.

Aumentar la representación diversa mediante asociaciones y colaboraciones:

Colaboramos con pacientes, grupos de representación de pacientes, agencias reguladoras, profesionales del cuidado de la salud y organizaciones de la comunidad para identificar e implementar soluciones que deriven en una representación diversa, que mejoren la igualdad en materia de salud y que generen pruebas para dar un mejor apoyo a los resultados de los pacientes.

Astrocitos y microglías

Mantener las neuronas en buen estado es importante para hacer cosas como moverse o para recordar cosas. Es aquí donde entran en juego los astrocitos y las microglías. Estas son células del cerebro que eliminan los desechos y protegen a las neuronas del daño físico y químico.

La enfermedad de Alzheimer distorsiona el equilibrio que mantiene a las neuronas en buen estado. Esto puede ocurrir una década o más antes de que la persona comience a tener síntomas.2

Beta amiloide y tau

La investigación sugiere que hay dos proteínas involucradas en los cambios que ocurren en el cerebro a causa de la enfermedad de Alzheimer: beta amiloide y tau.3 Por motivos que todavía se desconocen, estas proteínas se vuelven tóxicas y causan problemas en el cerebro.
  • La proteína beta amiloide se acumula en masas y forma placa. Estas placas de amiloide se acumulan entre las neuronas.
  • La proteína tau se acumula dentro de las neuronas y con el tiempo forma ovillos.
Mientras la placa de amiloide se acumula, la proteína tau se esparce rápidamente por el cerebro. Esto resulta demasiado para los astrocitos y las microglías. Como las microglías ya no pueden eliminar con eficiencia los desechos y los astrocitos quedan sometidos a situaciones de gran esfuerzo, se produce una inflamación crónica en el cerebro.4

Con el tiempo, las neuronas ya no pueden comunicarse y mueren.

Hipocampo

Cuando las neuronas mueren, el cerebro se encoge. El daño con frecuencia comienza en el hipocampo, que es responsable del aprendizaje y la memoria.2 Cuanto mayor sea la cantidad de neuronas que mueren, la persona que tiene enfermedad de Alzheimer menos podrá pensar, recordar, tomar decisiones o funcionar de manera independiente.4

Los estudios de investigación clínica están explorando opciones para detener o retrasar la aparición de problemas de memoria y pensamiento asociados a la enfermedad de Alzheimer. Si usted o un ser querido está afectado, la investigación clínica podría ofrecerles opciones.

Neuronas

Por ejemplo, consideremos qué sucede cuando mira esta imagen. Cuando miramos, gritamos, caminamos o recordamos, es el resultado de señales que se transmiten a través de los 100 000 millones de células nerviosas que tenemos en el cerebro, llamadas neuronas.

Estas neuronas se comunican entre sí mediante señales eléctricas. Estas señales pueden generar suficiente electricidad como para encender una bombilla de luz de bajo consumo.1 La combinación de estas señales eléctricas y químicas es responsable de las acciones que se mencionan anteriormente.

YOU ARE NOW LEAVING THIS WEBSITE

You are now leaving lillyADresearch.com and being redirected to a website that is not operated by Clinical Trial Media, Inc. Please be aware, Clinical Trial Media, Inc. is not responsible for the content or availability of this website and its privacy and security policies may differ from those on this website.

YOU ARE NOW LEAVING THIS WEBSITE

You are now leaving lillyADresearch.com and being redirected to a website that is not operated by Clinical Trial Media, Inc. Please be aware, Clinical Trial Media, Inc. is not responsible for the content or availability of this website and its privacy and security policies may differ from those on this website.

Neurons

See how you’re staring at this image? When we stare, shout, walk, or remember, it’s the result of signals passing through the 100 billion nerve cells in our brain called neurons.

Electrical charges help these neurons talk to each other. These charges can generate enough electricity to power a low-wattage bulb!1 The combination of these electrical and chemical signals is responsible for the actions mentioned above.

Hippocampus

As neurons die, the brain shrinks. The damage often starts in the hippocampus, which is responsible for learning and memory.2 The more neurons die, the less a person with Alzheimer’s disease is able to think, remember, make decisions, or function independently.4

Clinical research studies are exploring ways to stop or slow down the appearance of memory and thinking problems associated with Alzheimer’s disease. If you or a loved one is affected, there may be options through clinical research.

Beta-Amyloid and Tau

Research suggests that two proteins are involved in driving changes to the brain due to Alzheimer’s disease: beta-amyloid and tau.3 For reasons still unknown, these proteins become toxic and cause problems in the brain.
  • Beta-amyloid clumps together to form plaque. These amyloid plaques build up between neurons.
  • Tau accumulates inside neurons and eventually forms tangles.
As amyloid plaque builds up, tau spreads rapidly through the brain. It’s too much for astrocytes and microglia to deal with. Because microglia are no longer able to keep up with clearing debris and astrocytes become stressed, chronic inflammation occurs within the brain.4

Eventually, neurons can no longer communicate, and they die.

Astrocytes and Microglia

Keeping the neurons healthy is important to do things like move or remember things. This is where astrocytes and microglia come in. These are cells in the brain that clear away debris and protect neurons from physical or chemical damage.

Alzheimer’s disease disrupts the balance that keeps neurons healthy. This may happen a decade or more before a person starts to show symptoms.2

These goals guide Lilly’s work:

Create a Robust Clinical Research Study Strategy and Reach Diverse Populations

Our teams aim for each study’s participants to match the composition of the patient population that might use that study’s medicine if it’s approved. Across research studies globally, we identify and address barriers that keep underrepresented populations from participating.

Intentionally Select a Diverse Range of Sites and Investigators

We aim to recruit more research study investigators and external advisors who represent women and racial/ethnic minority populations, with the ultimate goal of having our investigators and advisors match the composition of the patient population in terms of gender and race/ethnicity.

Increase Diverse Representation through Partnerships and Collaborations

We collaborate with patients, patient advocacy groups, regulatory agencies, healthcare professionals, and community organizations to identify and implement solutions that will result in diverse representation, improve health equity, and generate evidence to support better patient results.